NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

Search

Coloplast A-S (Class B)

Закрыт

602 -0.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

595

Макс.

610

Ключевые показатели

By Trading Economics

Доход

-132M

912M

Продажи

-96M

6.9B

P/E

Средняя по отрасли

30.208

50.291

Прибыль на акцию

4.34

Дивидендная доходность

3.61

Рентабельность продаж

13.16

Сотрудники

16,741

EBITDA

-42M

2.2B

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+11.86% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.61%

2.40%

Следующий отчет о доходах

19 авг. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-19B

138B

Предыдущая цена открытия

602.23

Предыдущая цена закрытия

602

Coloplast A-S (Class B) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 июн. 2025 г., 23:49 UTC

Отчет

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 июн. 2025 г., 22:19 UTC

Приобретения, слияния, поглощения

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 июн. 2025 г., 21:30 UTC

Отчет

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 июн. 2025 г., 21:07 UTC

Отчет

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 июн. 2025 г., 23:49 UTC

Обсуждения рынка

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 июн. 2025 г., 23:39 UTC

Обсуждения рынка

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 июн. 2025 г., 23:34 UTC

Приобретения, слияния, поглощения

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 июн. 2025 г., 23:33 UTC

Приобретения, слияния, поглощения

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 июн. 2025 г., 23:32 UTC

Приобретения, слияния, поглощения

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 июн. 2025 г., 23:32 UTC

Приобретения, слияния, поглощения

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 июн. 2025 г., 23:31 UTC

Приобретения, слияния, поглощения

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 июн. 2025 г., 23:31 UTC

Приобретения, слияния, поглощения

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 июн. 2025 г., 23:30 UTC

Приобретения, слияния, поглощения

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 июн. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 июн. 2025 г., 23:19 UTC

Приобретения, слияния, поглощения

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 июн. 2025 г., 22:06 UTC

Отчет

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 июн. 2025 г., 21:15 UTC

Отчет

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 июн. 2025 г., 21:07 UTC

Приобретения, слияния, поглощения

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 июн. 2025 г., 21:07 UTC

Приобретения, слияния, поглощения

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 июн. 2025 г., 21:07 UTC

Приобретения, слияния, поглощения

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 июн. 2025 г., 21:07 UTC

Отчет

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 июн. 2025 г., 21:06 UTC

Приобретения, слияния, поглощения

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 июн. 2025 г., 21:06 UTC

Приобретения, слияния, поглощения

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 июн. 2025 г., 21:06 UTC

Обсуждения рынка

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 июн. 2025 г., 21:05 UTC

Приобретения, слияния, поглощения

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 июн. 2025 г., 21:05 UTC

Приобретения, слияния, поглощения

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 июн. 2025 г., 20:52 UTC

Отчет

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 июн. 2025 г., 20:51 UTC

Отчет

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 июн. 2025 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

26 июн. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Coloplast A-S (Class B) Прогноз

Целевая цена

By TipRanks

11.86% рост

Прогноз на 12 месяцев

Средняя 901.38 DKK  11.86%

Максимум 1,056 DKK

Минимум 720 DKK

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Coloplast A-S (Class B) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

8 ratings

2

Покупка

4

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.